Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06686524 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

Name: Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) — clinical trial record (NCT06686524)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorChongqing Precision Biotech Co., Ltd

Started2024-11-11

View on ClinicalTrials.gov ↗

Chongqing Precision Biotech Co., Ltd

36 trials monitored

See 1 trial at risk

This study is an open-label, single-arm, dose-escalation trial primarily designed to evaluate the safety and efficacy of a universal CAR-T cell therapy targeting CD19 in the treatment of patients with RJDM. Additionally, the study aims to characterize its pharmacokinetic and pharmacodynamic properties, explore its role in immune system reconstitution, and assess long-term survival benefits.

Trial Details

NCT Number	NCT06686524
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Dermatomyositis, Juvenile, Dermatomyositis
Enrollment	18 participants
Start Date	2024-11-11
Primary Completion	2026-11-10 (estimated)
Study Completion	2027-11-10 (estimated)
Updated on ClinicalTrials.gov	2024-11-13